* Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y.,and its collaborator were issued two U.S. patents, No.5,453,361 covering production of recombinant humanbrain-derived neurotrophic factor, and No. 5,438,121,covering BDNF proteins and compositions.
* Somatix Therapy Corp., of Alameda, Calif., was issuedU.S. patent No. 5,449,614 covering the use of apackaging cell line to produce non-replicating retroviralvectors for human gene therapy.
* Texas Biotechnology Corp., of Houston, was issuedU.S. patent No. 5,444,050 covering a series of selectinantagonists that were developed using structure-baseddesign technologies.
(c) 1997 American Health Consultants. All rights reserved.